Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announces it has raised $52 million in a Series C extension round led by new investors Pictet Alternative Advisors and Vivo Capital. Existing investors, SV Health Investors, Jeito Capital, SR One, IP Group plc, F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc., Adjuvant Capital, Asahi Kasei Pharma, Longwood Fund, and the Cystic Fibrosis Foundation, also participated. This brings the total raise for Series C to $147.5 million.
The full text of the press release can be found here.